Single-Cell Immune Signal Profiling for Early Preeclampsia Prognosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tests for preeclampsia are unreliable in detecting the condition early in pregnancy, leading to irreversible harm to mothers and fetuses due to delayed treatment.
Innovation Solution
High-dimensional mass cytometry and fluorescence-based flow cytometry immunoassays are used to characterize dynamic changes in immune cell features in maternal blood, analyzing immune cell subsets and signaling responses starting from the first trimester to identify individuals at high risk of preeclampsia through markers like pSTAT5 levels in CD4+ T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current diagnostic tests are used for preeclampsia detection, then treatment can be initiated, but diagnosis occurs only after signs and symptoms appear, leading to irreversible harm
Solution Approach 1:
The patent applies preliminary action by measuring immune cell features and signaling responses (such as pSTAT5 levels in CD4+ T cells) during the first and second trimesters to identify women at high risk of preeclampsia before clinical symptoms develop. This allows treatment to be initiated in advance, preventing irreversible harm to mother and fetus.
2Loss of time
If early diagnosis methods are developed, then treatment can be started before symptoms, but no current test reliably detects preeclampsia early
Solution Approach 1:
The patent replaces conventional mechanical/chemical diagnostic tests with mass cytometry technology to measure immune cell features and signaling responses. This substitution enables reliable early detection of preeclampsia risk by quantifying specific immune markers (such as pSTAT5 phosphorylation levels) with high precision before clinical symptoms appear.
3Reliability
If mass cytometry analysis is performed to identify high-risk individuals, then early intervention is enabled, but complex immune cell feature analysis is required
Solution Approach 1:
The patent extracts specific critical immune cell features and signaling responses (such as pSTAT5 levels in CD4+ T cells, regulatory T cell function, and pro-inflammatory cytokine profiles) from the complex immune system for focused analysis. By concentrating on these key markers rather than analyzing all immune parameters, the system achieves high risk prediction accuracy while managing analytical complexity.
Data Source
AI summary
Multiparametric analysis is performed at the single cell level of biological samples obtained from an individual during pregnancy to obtain a determination of changes in immune cell subsets, which changes include, without limitation, altered activation states of proteins involved in signaling pathways. Changes occur in signaling pathways of these immune cells that are predictive of propensity to develop preeclampsia in the pregnancy.